- Home
- IBIO vs QNTM Comparison
IBIO vs QNTM Comparison
Compare IBIO & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- QNTM
- Stock Information
- Founded
- IBIO 2008
- QNTM 1998
- Country
- IBIO United States
- QNTM Canada
- Employees
- IBIO N/A
- QNTM N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- QNTM
- Sector
- IBIO Health Care
- QNTM
- Exchange
- IBIO Nasdaq
- QNTM NYSE
- Market Cap
- IBIO 9.3M
- QNTM 8.7M
- IPO Year
- IBIO N/A
- QNTM N/A
- Fundamental
- Price
- IBIO $0.73
- QNTM $9.15
- Analyst Decision
- IBIO Strong Buy
- QNTM
- Analyst Count
- IBIO 3
- QNTM 0
- Target Price
- IBIO $4.87
- QNTM N/A
- AVG Volume (30 Days)
- IBIO 2.3M
- QNTM 101.1K
- Earning Date
- IBIO 05-02-2025
- QNTM 05-06-2025
- Dividend Yield
- IBIO N/A
- QNTM N/A
- EPS Growth
- IBIO N/A
- QNTM N/A
- EPS
- IBIO N/A
- QNTM N/A
- Revenue
- IBIO $375,000.00
- QNTM N/A
- Revenue This Year
- IBIO $36.00
- QNTM N/A
- Revenue Next Year
- IBIO N/A
- QNTM N/A
- P/E Ratio
- IBIO N/A
- QNTM N/A
- Revenue Growth
- IBIO 650.00
- QNTM N/A
- 52 Week Low
- IBIO $0.64
- QNTM $2.70
- 52 Week High
- IBIO $6.89
- QNTM $25.35
- Technical
- Relative Strength Index (RSI)
- IBIO 24.07
- QNTM 62.27
- Support Level
- IBIO $0.75
- QNTM $7.96
- Resistance Level
- IBIO $0.82
- QNTM $9.45
- Average True Range (ATR)
- IBIO 0.14
- QNTM 0.72
- MACD
- IBIO 0.10
- QNTM 0.10
- Stochastic Oscillator
- IBIO 3.04
- QNTM 90.00
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.